Evidence map›Paper›PMID 40259400›Full record

ArticleJournal of translational medicine2025

Efficacy of MET-targeting CAR T cells against glioblastoma patient-derived xenograft models.

Anna Qin, Anna Musket, Benjamin Hilton, Johanna Preiszner, Giedre Krenciute, Michael E Berens, Mingyao Ying, Phillip R Musich, Qian Xie

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of translational medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Anna Qin *Department of Biomedical Sciences, Quillen College of Medicine, East Tennessee State University, 1276 Gilbreath Dr, Johnson City, TN, 37614, USA.
Anna Musket *Department of Biomedical Sciences, Quillen College of Medicine, East Tennessee State University, 1276 Gilbreath Dr, Johnson City, TN, 37614, USA.
Benjamin HiltonCytogenetics Laboratory, Greenwood Genetic Center, Greenwood, SC, 29646, USA.
Johanna PreisznerDepartment of Pathology, Quillen College of Medicine, East Tennessee State University, Johnson City, TN, 37604, USA.
Giedre KrenciuteDepartment of Bone Marrow Transplantation and Cellular Therapy, St. Jude Children's Research Hospital, Memphis, TN, 38105, USA.
Michael E BerensClinical Genomics and Therapeutics Division, Translational Genomics Research Institute, Phoenix, AZ, 85004, USA.
Mingyao YingDepartment of Neurology, Hugo W. Moser Research Institute at Kennedy Krieger, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
Phillip R MusichDepartment of Biomedical Sciences, Quillen College of Medicine, East Tennessee State University, 1276 Gilbreath Dr, Johnson City, TN, 37614, USA.
Qian XieDepartment of Biomedical Sciences, Quillen College of Medicine, East Tennessee State University, 1276 Gilbreath Dr, Johnson City, TN, 37614, USA. xieq01@etsu.edu.ORCID 0000-0003-4206-1736

Funding

Characterization of MET alteration using glioblastoma patient-derived xenograft modelsR03NS120062 · NINDS · EAST TENNESSEE STATE UNIVERSITY · PI XIE, QIAN · 2021 to 2022
$143k
East Tennessee State University 825-30East Tennessee State University E85078East Tennessee State University E85096East Tennessee State University Research Enhancement Award 2023NINDS NIH HHS NS120062-01A1NINDS NIH HHS R03 NS120062
6 · The paper itself

Abstract

backgroundGenetic alteration of the MET receptor tyrosine kinase frequently occurs in glioblastoma (GBM). Clinically, bevacizumab treatment results in MET signaling activation, leading to GBM recurrence with a more malignant phenotype. While MET has been a promising therapeutic target, MET inhibitors have not been successful in treating GBM patients. MET-directed chimeric antigen receptor (CAR) T cells hold the promise of targeting MET-positive GBM regardless of genetic alterations or kinase activity.

methodsGBM patient-derived xenografts (PDX) harboring MET amplification (MET

resultsAlthough GBM are heterogeneous tumors, neuro-sphere cells isolated from MET

conclusionsWhereas MET inhibitors are effective in MET-active tumors, MET-CAR T cells eradicate MET-positive GBM growth in an antigen-dependent manner, demonstrating a promising therapeutic approach for treating MET-positive GBM. MET overexpression, especially MET

Indexed as

Brain NeoplasmsGlioblastomaImmunotherapy, AdoptiveProto-Oncogene Proteins c-metReceptors, Chimeric AntigenT-LymphocytesXenograft Model Antitumor AssaysAnimalsCell Line, TumorHumansMiceNeoplastic Stem CellsMET protein, humanProto-Oncogene Proteins c-metReceptors, Chimeric AntigenCancer immunotherapyChimeric antigen receptor T cell therapyGlioblastomaGlioma stem cellsMET-targeted therapy

Identifiers

PMID40259400
PMCPMC12013037

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.